TPM3 and thyroid cancer: Preliminary clinical activity of DS-6051b was observed in TKI-naive and crizotinib-pretreated ROS1+ NSCLC patients and a patient with TPM3-NTRK fusion-positive thyroid cancer who achieved a confirmed partial response of 27 months at the last follow-up (104, 105).